Gilead buys Kite Pharma for $11.9 BN, page-27

First 27 Last

Share
Profile

Follow
Whatsamadoovie

3,603 Posts.

685

11/09/17

02:41

Post #: 27119265
Share

Originally posted by DavieJones ↑

Well spotted ! Looks like a late addition

The MITCI (Phase 1b) study. A novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients with or without previous immune checkpoint therapy treatment.
B. Curti S. Hallmeyer J. Richards R. Andtbacka M. Faries G. Daniels M. Grose D. Shafren

Background

CAVATAK is a novel bio-selected oncolytic and immunotherapeutic strain of Coxsackievirus A21 (CVA21). In a phase 2 study, intratumoral (i.t.) CVA21 injection of advanced melanoma lesions resulted in increases in tumor immune-cell infiltration, up-regulation of γ-INF response and immune-checkpoint genes, including CD122 which may be a potential prognostic marker for enhanced anti-tumor activity by anti-CTLA-4 blockade strategies.

Methods

The Phase Ib MITCI study (NCT02307149) is investigating the efficacy and safety of i.t. CVA21 and i.v. ipilimumab in up to 70 pts with treated or untreated unresectable Stage IIIB-IVM1c melanoma. Pts received up to 3 x 108 TCID50 CVA21 i.t. on study days 1, 3, 5, 8 and 22, and then q3w for a further 6 series of injections. Ipilimumab (3 mg/kg) q3w was given as 4 i.v. infusions starting at Day 22.

Results

At present no DLT’s have been reported in the 30 pts currently enrolled. Combination treatment has been generally well-tolerated with surprisingly only two Gr 3 or higher treatment-related AE being ipilimumab-related fatigue and elevated liver enzymes. Currently, of the first 23 pts eligible for investigator response assessment, the confirmed ORR for the ITT population is 48.0% (11/23), with the ORR for immune checkpoint-naïve pts being 64% (7/11) and previous immune checkpoint therapy pts being 33% (4/12). Of note, is the encouraging ORR of 50% (4/8 pts) in pts with stage IVm1c disease. The DCR (CR+PR+SD) on the ITT population is currently 74% (17/23) of which > 66% of patients have been administered prior systemic therapy(s) with DCR of 88% (7/8) in pts with stage IVm1c disease.

Conclusions

Treatment of pts with CVA21 and ipilimumab has demonstrated durable response with minimal toxicity. The combination immunotherapy treatment has displayed anti-tumor activity in local, visceral and non-visceral lesions. Finally, responses are observed in patients with disease progression following immune checkpoint inhibitor therapy, suggesting the additive therapeutic benefit of CVA21 with ipilimumab.

Clinical trial identification

NCT02307149

Expand

Amazing overall response rate of 74% because of CVA21.

"suggesting the additive therapeutic benefit of CVA21 with ipilimumab.".

VLA Price at posting: 90.0¢ Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

Reporting wrap: Inghams, Accent, Mayne Pharma

How flooding did Strategic Energy Resources a favour: Four holes down in 'redesigned' gold & copper campaign

RDN

Raiden gears up for exploration in final quarter of 2024

The Rising Tide: How institutional adoption is shaping the future of crypto

The business of sport: Warren Tredrea's take on this week's news

Dale Gillham's weekly wrap: responding to a weak iron ore price with investing decisions

CC9

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

Week 34 Wrap: HotCopper's top watched; Oz banks cut saver interest; Kamala’s 28% corporate tax; AI’s back

NRX

Noronex kicks off EM survey at Humpback, Namibia – part of South32's earn-in deal to access Kalahari Copper Belt

IPH

IPH raises $100M to buy up Canadian IP firm Bereskin & Parr

There are more pages in this discussion • 5 more messages in this thread...

First 27 Last

Add VLA (ASX) to my watchlist

Gilead buys Kite Pharma for $11.9 BN, page-27

Top Stories

Reporting wrap: Inghams, Accent, Mayne Pharma

How flooding did Strategic Energy Resources a favour: Four holes down in 'redesigned' gold & copper campaign

Raiden gears up for exploration in final quarter of 2024

The Rising Tide: How institutional adoption is shaping the future of crypto

The business of sport: Warren Tredrea's take on this week's news

Dale Gillham's weekly wrap: responding to a weak iron ore price with investing decisions

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

Week 34 Wrap: HotCopper's top watched; Oz banks cut saver interest; Kamala’s 28% corporate tax; AI’s back

Noronex kicks off EM survey at Humpback, Namibia – part of South32's earn-in deal to access Kalahari Copper Belt

IPH raises $100M to buy up Canadian IP firm Bereskin & Parr

Featured News